Loading…
Sectoral / Thematic · Invesco Mutual Fund · AMFI code 154544Invesco India Pharma and Healthcare Fund
Disclosed for 1 months, Sep 2026 to Sep 2026.Published as: Invesco India Pharma and Healthcare Fund (An open ended equity scheme investing in Pharma, Healthcare and allied sectors)
Portfolio value
₹436 Cr
Sep 2026
- Stocks held
- 13
- Top 10 weight
- 75.4%
- of the portfolio in its ten largest
- Cash & debt
- 13.0%
- cash, money market and debt
- Moves this month
- —
- no earlier month
Invesco India Pharma and Healthcare Fund is an active equity fund in the Sectoral / Thematic category from Invesco Mutual Fund. In September 2026 it disclosed 13 stocks worth ₹436 Cr. Its largest positions were Max Healthcare Institute Limited (9.6%), Sun Pharmaceutical Industries Limited (9.0%), Sai Life Sciences Limited (8.6%); the ten largest together made up 75.4% of the portfolio, and Healthcare Services was the biggest sector at 52.4% of its equity. Cash and debt stood at 13.0%.
Against 229 other Sectoral / Thematic funds
Concentration
96%
Top-10 weight is higher than 96% of peers
Breadth
1%
Holds more stocks than 1% of peers
Cash
98%
Holds more cash than 98% of peers
What these mean: concentration · cash
Holdings in September 2026
Download CSVEvery line the fund disclosed, with the change against the previous month. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Cash, TREPS & receivables | 12.99% | — | ₹56.6 Cr | — | |
| Max Healthcare Institute Limited | 9.58% | — | ₹41.7 Cr | — | |
| Sun Pharmaceutical Industries Limited | 8.99% | — | ₹39.2 Cr | — | |
| Sai Life Sciences Limited | 8.63% | — | ₹37.6 Cr | — | |
| Apollo Hospitals Enterprise Limited | 8.03% | — | ₹35 Cr | — | |
| Manipal Health Enterprises Ltd | 7.98% | — | ₹34.7 Cr | — | |
| Divi's Laboratories Limited | 7.85% | — | ₹34.2 Cr | — | |
| Global Health Limited | 7.00% | — | ₹30.5 Cr | — | |
| Dr Agarwals Health Care Limited | 6.32% | — | ₹27.5 Cr | — | |
| Corona Remedies Limited | 6.13% | — | ₹26.7 Cr | — | |
| Torrent Pharmaceuticals Limited | 4.93% | — | ₹21.5 Cr | — | |
| Glenmark Pharmaceuticals Limited | 4.86% | — | ₹21.2 Cr | — | |
| Krishna Institute Of Medical Sciences Limited | 4.72% | — | ₹20.6 Cr | — | |
| Aster DM Healthcare Limited | 1.99% | — | ₹8.7 Cr | — |
What changed
This is the earliest month on record for the fund.
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
No earlier month with a sector split to compare against.
Allocation in Sep 2026
- Healthcare Services (7)52.4%
- Pharmaceuticals & Biotechnology (6)47.6%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Sep 2026
13.0%
- Cash alone
- 13.0%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- —
- lowest to highest · record 13.0% in Sep 2026
Not enough months to draw.
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.
Not enough months to draw.
All 1 months
| Month | Portfolio value | Stocks | Entered | Exited | Cash | Cash & debt | Turnover |
|---|---|---|---|---|---|---|---|
| Sep 2026 | ₹436 Cr | 13 | 13.0% | 13.0% | 0% |